Australia's most trusted
source of pharma news
Posted 8 February 2024 AM
Vertex Pharmaceuticals has revealed it has improved on its jackpot cystic fibrosis medication Trikafta with a "vanza triple", announcing its potential for "halting the disease before it starts" in children.
The company this week reported it would apply to drug regulators in the US and Europe for its once-daily combined treatment of vanzacaftor, tezacaftor and deutivacaftor.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.